<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694873</url>
  </required_header>
  <id_info>
    <org_study_id>perineal pain</org_study_id>
    <nct_id>NCT03694873</nct_id>
  </id_info>
  <brief_title>Oral Tramadol Versus Oral Celecoxib for Post-perineal Repair Analgesia</brief_title>
  <official_title>Oral Tramadol Versus Oral Celecoxib for Post-perineal Repair Analgesia After Spontaneous Vaginal Birth in Obese Women: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be performed to compare the effectiveness of oral tramadol versus oral
      celecoxib for the management of perineal pain following episiotomy or perineal tear repair
      after spontaneous vaginal birth in obese women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain after episiotomy or tear of perineal tissues during childbirth is often inadequately
      treated and may be severe. Not only did perineal pain negatively affect the physical and
      mental functioning of the woman, but also it might decrease the success of breastfeeding and
      reduced her ability to care for her child. The methods of relieving perineal pain included
      medication and non-medication. When the perineal pain was mild, the most common analgesic
      used was acetaminophen. Whereas the perineal pain was more severe, other drugs had been
      chosen such as opioid, non-opioid, and a combination of both opioid and non-opioid analgesics
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 10, 2018</start_date>
  <completion_date type="Anticipated">December 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>perineal pain</measure>
    <time_frame>1 hour after repair of episiotomy</time_frame>
    <description>perineal pain severity using visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>perineal pain</measure>
    <time_frame>1 hours after repair of episiotomy</time_frame>
    <description>perineal pain severity using visual analogue scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Perineal Pain</condition>
  <arm_group>
    <arm_group_label>tramadol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one tablet of Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride</intervention_name>
    <description>one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.</description>
    <arm_group_label>tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib 200mg</intervention_name>
    <description>Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.</description>
    <arm_group_label>celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:18-35 years

          -  Obese women with BMI ≥ 30.

          -  completed full 37-weeks gestation.

          -  spontaneous vaginal delivery with medio-lateral episiotomy or perineal tear requiring
             repair.

          -  Singleton alive fetus.

        Exclusion Criteria:

          -  known allergy to investigated drugs(tramadol or celecoxib).

          -  regular use of analgesic drugs before or during pregnancy.

          -  any medical condition known to be potentially exacerbated by opioids, including
             alimentary canal disorders, hepatic and renal disease.

          -  instrumental vaginal delivery.

          -  3rd or 4th degree perineal tear.

          -  severe postpartum haemorrhage (&gt;1,500 ml).

          -  complicating maternal diseases (pregestational/gestational diabetes mellitus; bleeding
             disorders; pre-eclampsia and other hypertensive disorders of pregnancy).

          -  epidural nor combined spinal-epidural analgesia in labour

          -  a history of peptic ulcer,asthma,thrombocytopaenia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AHMED SAMY, MD</last_name>
    <phone>01100681167</phone>
    <email>ahmedsamy8233@gmail.com</email>
  </overall_contact>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>lecturer in obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

